Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor

by Ali AK
Published 2011-08-01

Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting

by Ali AK, Hartzema AG
Published 2012-05-01

Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes

by Simeone JC, Bae JP, Hoogwerf BJ, Li Q, Haupt A, Ali AK, Boardman MK, Nordstrom BL
Published 2017-12-01

Tyrosine kinase domain mutations of EGFR gene in head and neck squamous cell carcinoma

by Vatte C, Al Amri AM, Cyrus C, Chathoth S, Acharya S, Hashim TM, Al Ali Z, Alshreadah ST, Alsayyah A, Al-Ali AK
Published 2017-03-01

Insight into Provider Payment Mechanisms in Healthcare Indus¬try: A Case of Iran

by Saeideh BABASHAHY, Abdolvahab BAGHBANIAN, Saeed MANAVI, Ali AK­BARI SARI, Alireza OLYAEE MANESH, Shahram GHAFFARI, Kambiz MONAZZAM, Raziyeh RONASIYAN, Abbas VOSOOGH, Hamid RAVAGHI, Saeed KERMANCHI, Seyyed Moussa TABATABAEI LOTFI, Fatemeh TORABI
Published 2016-05-01